This article is more than 5 years old. Information may no longer be current.
Lenalidomide active in recurrent ovarian cancer
Click Here to Manage Email Alerts
Continuous treatment with lenalidomide demonstrated activity in women with late recurrent ovarian cancer, according to results of a phase 2 study.
Frédéric Selle, MD, of the department of medical oncology at Assistance Publique — Hôpitaux de Paris in France, and colleagues assessed the safety and efficacy of continuous, daily 20 mg oral lenalidomide (Revlimid, Celgene) in 45 women with histologically-confirmed epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
Women had asymptomatic recurrence 6 months after prior therapy. Seventy-eight percent of women had serous histology; 73% had a single line of prior chemotherapy.
Efficacy assed by disease control at 4 months served as the primary outcome measure. PFS and safety served as secondary outcomes.
Results showed median platinum-free interval (PFI) was 11.3 months (range, 6.9-56.8). The clinical benefit rate at 4 months was 38% (95% CI, 23-53). Researchers reported a higher disease control rate among women PFI longer than 12 months compared with women whose PFI was between 6 and 12 months (59% vs. 24%; P=.023).
Overall, median PFS was 3.4 months (95% CI, 2.4-4.4).
Twenty-one patients achieved stable disease. Four patients demonstrated partial responses as defined by RECIST criteria. Eight patients demonstrated CA125 responses, including one who achieved a complete response.
Eight patients withdrew due to toxicities. Twenty-nine percent of patients developed grade 3 or grade 4 neutropenia. Other common toxicities included fatigue (69%), constipation (53%), abdominal pain (49%), diarrhea (38%), nausea/vomiting (36%) and thrombosis (11%).
“Lenalidomide shows interesting efficacy in late recurrent ovarian cancer patients,” Selle and colleagues wrote. “Future studies will evaluate combination of lenalidomide with chemotherapy agents.”
Disclosure: See the study for a full list of the researchers’ relevant financial disclosures.
Click Here to Manage Email Alerts